Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas

PURPOSE: In a head and neck squamous cell carcinoma (HNSCC) “window of opportunity” clinical trial, we reported that trametinib reduced MEK-Erk1/2 activation and resulted in tumor responses in a subset of patients. Here, we investigated resistance to trametinib and molecular correlates in HNSCC cell...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Mudianto, Tenny, Campbell, Katie M., Webb, Jason, Zolkind, Paul, Skidmore, Zachary L., Riley, Rachel, Barnell, Erica K., Ozgenc, Ibrahim, Giri, Tusar, Dunn, Gavin P., Adkins, Douglas R., Griffith, Malachi, Egloff, Ann Marie, Griffith, Obi L, Uppaluri, Ravindra
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8046740/
https://ncbi.nlm.nih.gov/pubmed/33547198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-4179
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados